Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

A controlled trial of initial antiviral regimens for HIV-1 infection.

Parienti JJ.

N Engl J Med. 2010 Mar 4;362(9):854; author reply 855. doi: 10.1056/NEJMc0912879. No abstract available.

2.

Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.

Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, Di Pietro M, Re MC, Tinelli C, Zazzi M; ARCA Collaborative Group.

AIDS. 2010 Apr 24;24(7):1013-8. doi: 10.1097/QAD.0b013e328336e962.

PMID:
20124969
3.

The art of managing human immunodeficiency virus infection: a balancing act.

Reiss P.

Clin Infect Dis. 2009 Nov 15;49(10):1602-4. doi: 10.1086/644770. No abstract available.

PMID:
19842978
4.

Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.

Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, Van Laethem K, Alcaro S, Costa G, Tommasi C, Zaccarelli M, Narciso P, Antinori A, Ceccherini-Silberstein F, Balzarini J, Perno CF.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):336-44. doi: 10.1097/QAI.0b013e3181e6763f.

PMID:
20739898
5.

Oral preexposure prophylaxis for HIV--another arrow in the quiver?

Michael NL.

N Engl J Med. 2010 Dec 30;363(27):2663-5. doi: 10.1056/NEJMe1012929. Epub 2010 Nov 23. No abstract available.

6.

Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.

Redfield RR, Morrow JS.

Clin Infect Dis. 2008 Oct 1;47(7):984-5. doi: 10.1086/591802. No abstract available.

PMID:
18778234
7.

Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.

Landman GW, Soonawala D.

Clin Infect Dis. 2010 Apr 15;50(8):1200; author reply 1200. doi: 10.1086/651468. No abstract available.

PMID:
20233045
8.

Recent HIV-1 infection: to treat or not to treat, that is the question.

Tossonian H, Conway B.

J Infect Dis. 2012 Jan 1;205(1):10-2. doi: 10.1093/infdis/jir702. Epub 2011 Dec 15. No abstract available.

PMID:
22180623
9.

European CHMP issues positive opinion for Atripla.

[No authors listed]

AIDS Patient Care STDS. 2007 Nov;21(11):890. No abstract available.

PMID:
18338431
10.

FDA notifications. Updated Atripla label approved.

[No authors listed]

AIDS Alert. 2010 Mar;25(3):36. No abstract available.

PMID:
20629262
11.

[One year with Atripla. Changeover to complete HIV therapy in a single tablet has proven successful].

Warpakowski A.

MMW Fortschr Med. 2009 Apr 30;151(18):54-5. German. No abstract available.

PMID:
19769077
12.

Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.

Jenny-Avital ER.

N Engl J Med. 2006 Jun 8;354(23):2506-8; author reply 2506-8. No abstract available.

PMID:
16764056
13.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, Horton J, Ha B, Lanier ER, Elion R; COL40263 study.

J Antimicrob Chemother. 2010 Feb;65(2):307-15. doi: 10.1093/jac/dkp419. Epub 2009 Dec 15.

14.

Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.

Parienti JJ.

J Antimicrob Chemother. 2009 May;63(5):1080; author reply 1080-1. doi: 10.1093/jac/dkn556. Epub 2009 Jan 21. No abstract available.

PMID:
19158108
15.
16.

Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.

Tamalet C, Tomei C, Henry M, Solas C, Villacian J, Colson P.

AIDS. 2007 Nov 30;21(18):2551-2. No abstract available.

PMID:
18025898
17.

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A.

Clin Infect Dis. 2009 Nov 15;49(10):1591-601. doi: 10.1086/644769.

PMID:
19842973
18.

[Simply convincing. New fixed combination for HIV therapy].

[No authors listed]

MMW Fortschr Med. 2005 Apr 25;147 Spec No 1:20-3. German. No abstract available.

PMID:
16385865
19.

Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.

Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.

J Antimicrob Chemother. 2009 Dec;64(6):1260-4. doi: 10.1093/jac/dkp348. Epub 2009 Sep 22.

PMID:
19776037
20.

High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.

Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.

J Antimicrob Chemother. 2009 Feb;63(2):380-8. doi: 10.1093/jac/dkn471. Epub 2008 Nov 25.

PMID:
19036752

Supplemental Content

Support Center